Yasunori Sato
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Yasunori Sato has a total of 346 co-authors. Here are the top co-authors by number of shared publications:
- Kengo Nagashima
Biostatistics Unit, Clinical and Translational Research Center, Keio University Hospital, Tokyo, Japan
4 shared publications - Hiroshi Itoh
Department of Endocrinology, Metabolism and Nephrology, Keio University School of Medicine, Tokyo, Japan
3 shared publications - Shu Meguro
Division of Nephrology, Endocrinology and Metabolism, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan
3 shared publications - Akihiro Koreki
Department of Neuropsychiatry, Keio University School of Medicine, Tokyo, Japan
2 shared publications - Akiko Nakagawa
Research Center for Child Mental Development, Chiba University, Chiba, Japan
2 shared publications - Akiko Yokoi
Department of Pediatric Surgery, Kobe Children's Hospital, Kobe, Japan
2 shared publications
Latest Publications
- Open Access
- 17 November 2026
- Published by JMIR Publications Inc. in JMIR mHealth and uHealth
- Vol. 14, e113548
Correction: Efficacy and Safety of a Telemedicine System in Patients With Gestational Diabetes Mellitus (TELEGLAM): Single-Center, 2-Arm, Randomized, Open-Label, Parallel-Group Study
- 17 November 2026
- Published by JMIR Publications Inc. in JMIR mHealth and uHealth
- Vol. 14, e113548
Open AccessCorrection: Efficacy and Safety of a Telemedicine System in Patients With Gestational Diabetes Mellitus (TELEGLAM): Single-Center, 2-Arm, Randomized, Open-Label, Parallel-Group Study
- 7 November 2026
- Published by Wiley in Prenatal Diagnosis
Integrated Prenatal Cardiopulmonary Assessment Using Fetal Echocardiography in Isolated Left‐Sided Congenital Diaphragmatic Hernia
Objective: Prenatal severity assessment in congenital diaphragmatic hernia (CDH) primarily relies on lung‐based parameters such as the observed‐to‐expected lung‐to‐head ratio (o/eLHR) and liver position; however, these markers do not fully reflect fetal cardiopulmonary adaptation. We investigated the prognostic significance of fetal echocardiographic parameters and integrated these in prenatal prediction models in left‐sided CDH. Methods: This nationwide multicenter retrospective study included fetuses with prenatally diagnosed isolated left‐sided CDH. Gestational age‐adjusted Z‐scores were generated for fetal cardiac dimensions. Receiver operating characteristic analyses were performed to evaluate prognostic performance for survival. Results: A total of 363 fetuses were included, with an overall survival rate of 74.9%. Non‐survivors demonstrated significantly smaller right pulmonary artery and mitral valve dimensions than survivors. Among fetal echocardiographic parameters, the mitral‐to‐tricuspid valve ratio (MTR) demonstrated the strongest predictive performance, with an area under the curve (AUC) of 0.77. In fetuses evaluated at ≤ 29 weeks’ gestation, an exploratory model combining MTR with o/eLHR and liver‐up status achieved an apparent AUC of 0.827. Conclusion: Fetal echocardiographic parameters were associated with survival in CDH. Integrated prenatal cardiopulmonary assessment incorporating MTR may provide complementary prognostic information although independent external validation is required.
- 7 November 2026
- Published by Wiley in Prenatal Diagnosis
Integrated Prenatal Cardiopulmonary Assessment Using Fetal Echocardiography in Isolated Left‐Sided Congenital Diaphragmatic Hernia
Objective: Prenatal severity assessment in congenital diaphragmatic hernia (CDH) primarily relies on lung‐based parameters such as the observed‐to‐expected lung‐to‐head ratio (o/eLHR) and liver position; however, these markers do not fully reflect fetal cardiopulmonary adaptation. We investigated the prognostic significance of fetal echocardiographic parameters and integrated these in prenatal prediction models in left‐sided CDH. Methods: This nationwide multicenter retrospective study included fetuses with prenatally diagnosed isolated left‐sided CDH. Gestational age‐adjusted Z‐scores were generated for fetal cardiac dimensions. Receiver operating characteristic analyses were performed to evaluate prognostic performance for survival. Results: A total of 363 fetuses were included, with an overall survival rate of 74.9%. Non‐survivors demonstrated significantly smaller right pulmonary artery and mitral valve dimensions than survivors. Among fetal echocardiographic parameters, the mitral‐to‐tricuspid valve ratio (MTR) demonstrated the strongest predictive performance, with an area under the curve (AUC) of 0.77. In fetuses evaluated at ≤ 29 weeks’ gestation, an exploratory model combining MTR with o/eLHR and liver‐up status achieved an apparent AUC of 0.827. Conclusion: Fetal echocardiographic parameters were associated with survival in CDH. Integrated prenatal cardiopulmonary assessment incorporating MTR may provide complementary prognostic information although independent external validation is required.
- Open Access
- 14 September 2026
- Published by Springer Nature in BMC Pregnancy and Childbirth
Absence of retained placenta in a previous delivery does not predict its absence in a subsequent delivery: a retrospective cohort study
- 14 September 2026
- Published by Springer Nature in BMC Pregnancy and Childbirth
Open AccessAbsence of retained placenta in a previous delivery does not predict its absence in a subsequent delivery: a retrospective cohort study
- 28 July 2026
- Published by Wiley in Digestive Endoscopy
- Vol. 38 (8) , e70247
Clinical Outcomes of Underwater Endoscopic Submucosal Dissection for Duodenal Tumors: A Systematic Review and Meta‐Analysis
Background and Study Aim: Underwater endoscopic submucosal dissection (U‐ESD) has recently been introduced as a technique that may improve visualization and submucosal layer expansion. However, the clinical outcomes of U‐ESD for duodenal tumors have not been systematically evaluated. This study aimed to assess the efficacy and safety of U‐ESD for duodenal tumors through a systematic review and meta‐analysis. Patients and Methods: A comprehensive literature search was conducted using PubMed, Scopus, and the Cochrane Library from database inception to December 12, 2025. Studies evaluating U‐ESD for duodenal tumors were included. Primary outcomes included en bloc resection, R0 resection, procedure time, adverse events, and complete mucosal defect closure. Pooled estimates were calculated using a random‐effects model. Results: Four retrospective studies comprising 298 lesions treated with U‐ESD were included. The pooled procedure time was 59 min (95% CI, 48–70 min; I 2 = 72%). The pooled en bloc resection rate was 99% (95% CI, 97%–100%; I 2 = 0%), and the pooled R0 resection rate was 89% (95% CI, 81%–93%; I 2 = 54%). The pooled intraoperative perforation rate was 5% (95% CI, 1%–23%; I 2 = 88%). The pooled delayed perforation and delayed bleeding rates were 1% (95% CI, 0%–3%; I 2 = 0%) and 2% (95% CI, 1%–5%; I 2 = 0%), respectively. Conclusion: Current evidence suggests that U‐ESD is a feasible treatment option for duodenal tumors and is associated with favorable clinical outcomes. However, the available evidence remains limited, and potential biases and concerns regarding generalizability warrant cautious interpretation of these findings.
- 28 July 2026
- Published by Wiley in Digestive Endoscopy
- Vol. 38 (8) , e70247
Clinical Outcomes of Underwater Endoscopic Submucosal Dissection for Duodenal Tumors: A Systematic Review and Meta‐Analysis
Background and Study Aim: Underwater endoscopic submucosal dissection (U‐ESD) has recently been introduced as a technique that may improve visualization and submucosal layer expansion. However, the clinical outcomes of U‐ESD for duodenal tumors have not been systematically evaluated. This study aimed to assess the efficacy and safety of U‐ESD for duodenal tumors through a systematic review and meta‐analysis. Patients and Methods: A comprehensive literature search was conducted using PubMed, Scopus, and the Cochrane Library from database inception to December 12, 2025. Studies evaluating U‐ESD for duodenal tumors were included. Primary outcomes included en bloc resection, R0 resection, procedure time, adverse events, and complete mucosal defect closure. Pooled estimates were calculated using a random‐effects model. Results: Four retrospective studies comprising 298 lesions treated with U‐ESD were included. The pooled procedure time was 59 min (95% CI, 48–70 min; I 2 = 72%). The pooled en bloc resection rate was 99% (95% CI, 97%–100%; I 2 = 0%), and the pooled R0 resection rate was 89% (95% CI, 81%–93%; I 2 = 54%). The pooled intraoperative perforation rate was 5% (95% CI, 1%–23%; I 2 = 88%). The pooled delayed perforation and delayed bleeding rates were 1% (95% CI, 0%–3%; I 2 = 0%) and 2% (95% CI, 1%–5%; I 2 = 0%), respectively. Conclusion: Current evidence suggests that U‐ESD is a feasible treatment option for duodenal tumors and is associated with favorable clinical outcomes. However, the available evidence remains limited, and potential biases and concerns regarding generalizability warrant cautious interpretation of these findings.
- Open Access
- 8 May 2026
- Published by JMIR Publications Inc. in JMIR mHealth and uHealth
- Vol. 14, e72242
Efficacy and Safety of a Telemedicine System in Patients With Gestational Diabetes Mellitus (TELEGLAM): Single-Center, 2-Arm, Randomized, Open-Label, Parallel-Group Study
Background: In the management of gestational diabetes mellitus (GDM), the usual medical treatment requires frequent visits for glucose monitoring and insulin dose adjustment, and this imposes significant physical, psychological, and economic burdens on pregnant women. As mobile health platforms become increasingly integrated into diabetes care, telemedicine may help alleviate these burdens; however, evidence evaluating its effectiveness as a replacement for routine in-person GDM care remains limited. Objective: This study aims to evaluate the impact of telemedicine on the quality of life and costs for patients with GDM requiring insulin therapy. Methods: This single-center, 2-arm, randomized, open-label, parallel-group study included patients with GDM who started insulin injection therapy. Participants were randomized to either the telemedicine or standard face-to-face care groups for 10 (SD 2) weeks. The telemedicine intervention used a smartphone-linked platform that enabled the automatic transfer of glucose data from connected glucose meters and facilitated real-time video consultations. Primary end points included costs and patient satisfaction. Costs were assessed using claims data, transportation calculations, and wage-based productivity losses, while patient satisfaction was evaluated through changes in the Problem Areas in Diabetes Survey and Diabetes Therapy-Related Quality of Life questionnaire scores. Secondary outcomes included glycemic control and perinatal outcomes. Results: In total, 38 participants were included, with 18 assigned to the telemedicine group and 20 to the standard care group. Total costs (32,712, 95% CI 15,412‐50,013 vs 59,202, 95% CI 42,603‐75,800 Japanese yen; $284, 95% CI 134‐435 vs $515, 95% CI 370‐659, purchasing power parity [PPP]–adjusted; P =.01), direct non–health care costs (922, 95% CI −240 to 2084 vs 2561, 95% CI 1447‐3676 yen; $8, 95% CI −2 to 18 vs $22, 95% CI 13 to 32 PPP-adjusted; P =.02), and indirect costs (8981, 95% CI −7119 to 25,082 vs 32,832, 95% CI 17,384‐48,279 yen; $78, 95% CI −62 to 218 vs $285, 95% CI 151‐420 PPP-adjusted; P =.01) reduced significantly in the telemedicine group compared with the standard care group. The improvements in the Problem Areas in Diabetes Survey (−7.6, 95% CI −13.7 to −1.4; P =.02) and Diabetes Therapy–Related Quality of Life domain 1 (10.5, 95% CI 0.9-20.1; P =.03) scores from the baseline were significantly greater in the telemedicine group than that in the standard care group. Nonetheless, glycemic control and frequency of perinatal complications were comparable between the 2 groups. Consultation time was similar across groups, suggesting no added workload for clinicians. Conclusions: In this randomized trial, mobile health–enabled telemedicine safely replaced routine in-person visits for patients with GDM requiring insulin therapy. Telemedicine significantly reduced psychological and economic burdens without compromising glycemic or perinatal outcomes, demonstrating its value as a patient-centered and cost-efficient model of care. These findings support the broader implementation of mobile-based telemedicine approaches in GDM management.
- 8 May 2026
- Published by JMIR Publications Inc. in JMIR mHealth and uHealth
- Vol. 14, e72242
Open AccessEfficacy and Safety of a Telemedicine System in Patients With Gestational Diabetes Mellitus (TELEGLAM): Single-Center, 2-Arm, Randomized, Open-Label, Parallel-Group Study
Background: In the management of gestational diabetes mellitus (GDM), the usual medical treatment requires frequent visits for glucose monitoring and insulin dose adjustment, and this imposes significant physical, psychological, and economic burdens on pregnant women. As mobile health platforms become increasingly integrated into diabetes care, telemedicine may help alleviate these burdens; however, evidence evaluating its effectiveness as a replacement for routine in-person GDM care remains limited. Objective: This study aims to evaluate the impact of telemedicine on the quality of life and costs for patients with GDM requiring insulin therapy. Methods: This single-center, 2-arm, randomized, open-label, parallel-group study included patients with GDM who started insulin injection therapy. Participants were randomized to either the telemedicine or standard face-to-face care groups for 10 (SD 2) weeks. The telemedicine intervention used a smartphone-linked platform that enabled the automatic transfer of glucose data from connected glucose meters and facilitated real-time video consultations. Primary end points included costs and patient satisfaction. Costs were assessed using claims data, transportation calculations, and wage-based productivity losses, while patient satisfaction was evaluated through changes in the Problem Areas in Diabetes Survey and Diabetes Therapy-Related Quality of Life questionnaire scores. Secondary outcomes included glycemic control and perinatal outcomes. Results: In total, 38 participants were included, with 18 assigned to the telemedicine group and 20 to the standard care group. Total costs (32,712, 95% CI 15,412‐50,013 vs 59,202, 95% CI 42,603‐75,800 Japanese yen; $284, 95% CI 134‐435 vs $515, 95% CI 370‐659, purchasing power parity [PPP]–adjusted; P =.01), direct non–health care costs (922, 95% CI −240 to 2084 vs 2561, 95% CI 1447‐3676 yen; $8, 95% CI −2 to 18 vs $22, 95% CI 13 to 32 PPP-adjusted; P =.02), and indirect costs (8981, 95% CI −7119 to 25,082 vs 32,832, 95% CI 17,384‐48,279 yen; $78, 95% CI −62 to 218 vs $285, 95% CI 151‐420 PPP-adjusted; P =.01) reduced significantly in the telemedicine group compared with the standard care group. The improvements in the Problem Areas in Diabetes Survey (−7.6, 95% CI −13.7 to −1.4; P =.02) and Diabetes Therapy–Related Quality of Life domain 1 (10.5, 95% CI 0.9-20.1; P =.03) scores from the baseline were significantly greater in the telemedicine group than that in the standard care group. Nonetheless, glycemic control and frequency of perinatal complications were comparable between the 2 groups. Consultation time was similar across groups, suggesting no added workload for clinicians. Conclusions: In this randomized trial, mobile health–enabled telemedicine safely replaced routine in-person visits for patients with GDM requiring insulin therapy. Telemedicine significantly reduced psychological and economic burdens without compromising glycemic or perinatal outcomes, demonstrating its value as a patient-centered and cost-efficient model of care. These findings support the broader implementation of mobile-based telemedicine approaches in GDM management.
- Open Access
- 1 January 2026
- Published by Japan Endocrine Society in Endocrine Journal
- Vol. 73 (11) , 1203-1217
Study of weight loss intervention to find an effective strategy for obesity management and the TARGET of weight loss amount for reducing health disorders (SLIM-TARGET): a randomized controlled trial
This randomized controlled study aimed to clarify weight loss targets for improving obesity-related disorders in individuals with overweight or obesity. A total of 294 participants with six obesity-related conditions were assigned to either a standard or intensive treatment group, with 12-month weight loss targets of ≥3% and ≥7%, respectively. The standard group followed the Japanese Guidelines for the Management of Obesity Disease 2016. The intensive group received frequent nutritional guidance, enhanced diet and exercise therapy, and additional pharmacotherapy. The primary outcome was weight loss and improvement in at least two obesity-related disorders at 12 months. Secondary outcomes included remission of health disorders, improvement in at least one health disorder, and visceral fat reduction. At 12 months, the weight loss was –2.5% in the intensive group and –1.7% in the standard group, with no significant difference in the primary outcome. However, remission of health disorders was achieved in 16.9% of the intensive group compared with 6.2% of the standard group (adjusted odds ratio 3.079; 95% CI 1.075–8.823; p = 0.036). Visceral fat reduction was greater in the intensive group (–20.46 cm2 vs. –8.9 cm2; p = 0.039). Intensive treatment significantly improved blood pressure early and increased treatment motivation scores by 10.9% (95% CI: 1.2–20.6) at 24 months (p = 0.004). In both groups, ≥60% of the participants showed improvement in at least one disorder. Despite not achieving the target weight loss, resulting in no significant difference in the primary outcome, the intensive treatment increased remission percentages, improved early blood pressure control, and enhanced long-term treatment motivation. The study was registered at UMIN Clinical Trials Registry (UMIN ID: UMIN000031862).
- 1 January 2026
- Published by Japan Endocrine Society in Endocrine Journal
- Vol. 73 (11) , 1203-1217
Open AccessStudy of weight loss intervention to find an effective strategy for obesity management and the TARGET of weight loss amount for reducing health disorders (SLIM-TARGET): a randomized controlled trial
This randomized controlled study aimed to clarify weight loss targets for improving obesity-related disorders in individuals with overweight or obesity. A total of 294 participants with six obesity-related conditions were assigned to either a standard or intensive treatment group, with 12-month weight loss targets of ≥3% and ≥7%, respectively. The standard group followed the Japanese Guidelines for the Management of Obesity Disease 2016. The intensive group received frequent nutritional guidance, enhanced diet and exercise therapy, and additional pharmacotherapy. The primary outcome was weight loss and improvement in at least two obesity-related disorders at 12 months. Secondary outcomes included remission of health disorders, improvement in at least one health disorder, and visceral fat reduction. At 12 months, the weight loss was –2.5% in the intensive group and –1.7% in the standard group, with no significant difference in the primary outcome. However, remission of health disorders was achieved in 16.9% of the intensive group compared with 6.2% of the standard group (adjusted odds ratio 3.079; 95% CI 1.075–8.823; p = 0.036). Visceral fat reduction was greater in the intensive group (–20.46 cm2 vs. –8.9 cm2; p = 0.039). Intensive treatment significantly improved blood pressure early and increased treatment motivation scores by 10.9% (95% CI: 1.2–20.6) at 24 months (p = 0.004). In both groups, ≥60% of the participants showed improvement in at least one disorder. Despite not achieving the target weight loss, resulting in no significant difference in the primary outcome, the intensive treatment increased remission percentages, improved early blood pressure control, and enhanced long-term treatment motivation. The study was registered at UMIN Clinical Trials Registry (UMIN ID: UMIN000031862).
- 19 July 2025
- Published by Springer Nature in Annals of Biomedical Engineering
- Vol. 53 (10) , 2626-2637
Automated Quantitative Evaluation of Age-Related Thymic Involution on Plain Chest CT
The thymus is an important immune organ involved in T-cell generation. Age-related involution of the thymus has been linked to various age-related pathologies in recent studies. However, there has been no method proposed to quantify age-related thymic involution based on a clinical image. The purpose of this study was to establish an objective and automatic method to quantify age-related thymic involution based on plain chest computed tomography (CT) images. We newly defined the thymic region for quantification (TRQ) as the target anatomical region. We manually segmented the TRQ in 135 CT studies, followed by construction of segmentation neural network (NN) models using the data. We developed the estimator of thymic volume (ETV), a quantitative indicator of the thymic tissue volume inside the segmented TRQ, based on simple mathematical modeling. The Hounsfield unit (HU) value and volume of the NN-segmented TRQ were measured, and the ETV was calculated in each CT study from 853 healthy subjects. We investigated how these measures were related to age and sex using quantile additive regression models. A significant correlation between the NN-segmented and manually segmented TRQ was seen for both the HU value and volume (r = 0.996 and r = 0.986, respectively). ETV declined exponentially with age (p < 0.001), consistent with age-related decline in the thymic tissue volume. In conclusion, our method enabled robust quantification of age-related thymic involution. Our method may aid in the prediction and risk classification of pathologies related to thymic involution.
- 19 July 2025
- Published by Springer Nature in Annals of Biomedical Engineering
- Vol. 53 (10) , 2626-2637
Automated Quantitative Evaluation of Age-Related Thymic Involution on Plain Chest CT
The thymus is an important immune organ involved in T-cell generation. Age-related involution of the thymus has been linked to various age-related pathologies in recent studies. However, there has been no method proposed to quantify age-related thymic involution based on a clinical image. The purpose of this study was to establish an objective and automatic method to quantify age-related thymic involution based on plain chest computed tomography (CT) images. We newly defined the thymic region for quantification (TRQ) as the target anatomical region. We manually segmented the TRQ in 135 CT studies, followed by construction of segmentation neural network (NN) models using the data. We developed the estimator of thymic volume (ETV), a quantitative indicator of the thymic tissue volume inside the segmented TRQ, based on simple mathematical modeling. The Hounsfield unit (HU) value and volume of the NN-segmented TRQ were measured, and the ETV was calculated in each CT study from 853 healthy subjects. We investigated how these measures were related to age and sex using quantile additive regression models. A significant correlation between the NN-segmented and manually segmented TRQ was seen for both the HU value and volume (r = 0.996 and r = 0.986, respectively). ETV declined exponentially with age (p < 0.001), consistent with age-related decline in the thymic tissue volume. In conclusion, our method enabled robust quantification of age-related thymic involution. Our method may aid in the prediction and risk classification of pathologies related to thymic involution.
- Open Access
- 9 June 2025
- Published by Elsevier in ESMO Gastrointestinal Oncology
- Vol. 9
WJOG18524G: a single-arm phase II study evaluating bemarituzumab combined with ramucirumab and paclitaxel in fibroblast growth factor receptor 2b (FGFR2b)-positive advanced gastric or gastroesophageal junction cancer (RAINBIRD)
- 9 June 2025
- Published by Elsevier in ESMO Gastrointestinal Oncology
- Vol. 9
Open AccessWJOG18524G: a single-arm phase II study evaluating bemarituzumab combined with ramucirumab and paclitaxel in fibroblast growth factor receptor 2b (FGFR2b)-positive advanced gastric or gastroesophageal junction cancer (RAINBIRD)
- Open Access
- 1 January 2025
- Published by XMLink in Journal of Gastric Cancer
- Vol. 25 (3) , 455-465
Investigating the Synergistic Effects of Pembrolizumab and Chemotherapy in Gastric and Gastroesophageal Junction Cancer
Okui J, et al. J Gastric Cancer. 2025 Jun;25:e33. https://doi.org/10.5230/jgc.2025.25.e33
- 1 January 2025
- Published by XMLink in Journal of Gastric Cancer
- Vol. 25 (3) , 455-465
Open AccessInvestigating the Synergistic Effects of Pembrolizumab and Chemotherapy in Gastric and Gastroesophageal Junction Cancer
Okui J, et al. J Gastric Cancer. 2025 Jun;25:e33. https://doi.org/10.5230/jgc.2025.25.e33
- 30 December 2024
- Published by Springer Nature in Neurological Sciences
- Vol. 46 (4) , 1581-1597
Exercise therapy can effectively improve trunk performance and sitting balance in spinal cord injury: a systematic review and meta-analysis
Objective To determine the effects of exercise on trunk performance and balance in patients with spinal cord injury (SCI). Methods We searched the databases MEDLINE, Cochrane Library, EMBASE, Physiotherapy Evidence Database, Web of Science, PsycINFO, and CINAHL from inception to June 2020. Our search targeted studies such as randomized or non-randomized controlled trials and randomized crossover trials that evaluated the effects of exercise on trunk performance and balance in patients with SCI. Results Seventeen eligible studies with 432 patients with SCI were included in the meta-analysis. The exercise significantly improved several measures: Berg Balance Scale (mean differences [MD] = 4.58; 95% confidence intervals [CI], 0.35, 8.8; p = 0.03), Modified Functional Reach Test (MD = 5.29; 95% CI, 4.16, 6.42; p < 0.01), T-shirt test (MD = 5.62; 95% CI, − 3.82, − 7.42; p < 0.01), Timed Up and Go (MD = − 1.70; 95% CI, − 0.23, − 3.16; p = 0.02). Improvements were also noted in total static sitting balance (standardized mean differences [SMD] = 1.21; 95% CI, 0.79, 1.63; p < 0.01), and total dynamic sitting balance (SMD = 1.01; 95% CI, 0.30, 1.73; p < 0.01). In the subgroup analysis, exercise with sensory input enhancement significantly improved total static (SMD = 1.37; 95% CI, 0.64, 2.11; p < 0.01) and total dynamic sitting balance (SMD = 1.78; 95% CI, 0.28, 3.29; p = 0.02). Conclusions Exercise may improve sitting balance in patients with SCI. Moreover, enhancement of sensory input had an add-on effect in improving sitting balance. Registration: PROSPERO (CRD42020185904).
- 30 December 2024
- Published by Springer Nature in Neurological Sciences
- Vol. 46 (4) , 1581-1597
Exercise therapy can effectively improve trunk performance and sitting balance in spinal cord injury: a systematic review and meta-analysis
Objective To determine the effects of exercise on trunk performance and balance in patients with spinal cord injury (SCI). Methods We searched the databases MEDLINE, Cochrane Library, EMBASE, Physiotherapy Evidence Database, Web of Science, PsycINFO, and CINAHL from inception to June 2020. Our search targeted studies such as randomized or non-randomized controlled trials and randomized crossover trials that evaluated the effects of exercise on trunk performance and balance in patients with SCI. Results Seventeen eligible studies with 432 patients with SCI were included in the meta-analysis. The exercise significantly improved several measures: Berg Balance Scale (mean differences [MD] = 4.58; 95% confidence intervals [CI], 0.35, 8.8; p = 0.03), Modified Functional Reach Test (MD = 5.29; 95% CI, 4.16, 6.42; p < 0.01), T-shirt test (MD = 5.62; 95% CI, − 3.82, − 7.42; p < 0.01), Timed Up and Go (MD = − 1.70; 95% CI, − 0.23, − 3.16; p = 0.02). Improvements were also noted in total static sitting balance (standardized mean differences [SMD] = 1.21; 95% CI, 0.79, 1.63; p < 0.01), and total dynamic sitting balance (SMD = 1.01; 95% CI, 0.30, 1.73; p < 0.01). In the subgroup analysis, exercise with sensory input enhancement significantly improved total static (SMD = 1.37; 95% CI, 0.64, 2.11; p < 0.01) and total dynamic sitting balance (SMD = 1.78; 95% CI, 0.28, 3.29; p = 0.02). Conclusions Exercise may improve sitting balance in patients with SCI. Moreover, enhancement of sensory input had an add-on effect in improving sitting balance. Registration: PROSPERO (CRD42020185904).